Loading clinical trials...
Loading clinical trials...
A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer
Conditions
Interventions
epoetin alfa
filgrastim
+5 more
Locations
78
United States
Sparks-Arkansas Oklahoma Cancer Treatment Centre
Fort Smith, Arkansas, United States
Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States
Scripps Cancer Center
La Jolla, California, United States
University of Colorado Cancer Centre
Aurora, Colorado, United States
Greenwich Hospital - Bendheim Cancer Center
Greenwich, Connecticut, United States
Sibley Memorial Hospital, Oncology Research
Washington D.C., District of Columbia, United States
Start Date
December 4, 2000
Primary Completion Date
February 10, 2014
Completion Date
March 17, 2014
Last Updated
October 5, 2020
NCT07040891
NCT07547774
NCT06257264
NCT04740697
NCT07347600
NCT07525869
Lead Sponsor
NCIC Clinical Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions